---
title: "FDA clears Bristol’s oral CELMoD Zenbexus for advanced multiple myeloma; appeals court revives $6."
id: "stat-news-3-stat-pharmalittle-we-re-reading-about-a-lawsuit-over-lab-tests-for-meds-a"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-3-stat-pharmalittle-we-re-reading-about-a-lawsuit-over-lab-tests-for-meds-a"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/?utm_campaign=rss"
published_at: "2026-08-14T14:00:17.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA clears Bristol’s oral CELMoD Zenbexus for advanced multiple myeloma; appeals court revives $6.
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-3-stat-pharmalittle-we-re-reading-about-a-lawsuit-over-lab-tests-for-meds-a
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/?utm_campaign=rss)
- **Published At:** 2026-08-14T14:00:17.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The U.S. Food and Drug Administration approved an oral treatment for advanced **multiple myeloma** from **Bristol Myers Squibb**, branded as **Zenbexus**. The drug is the first in a new class of blood-cancer agents called **CELMoDs** and the first cleared using a more sensitive measure of remission. - **CELMoDs** are designed to redirect a cell’s natural protein-degradation machinery to eliminate cancer-causing proteins; Bristol developed Zenbexus as part of that effort. - A U.S. appeals court ruled that a lower court erred in dismissing a **$6.7 billion** lawsuit accusing **Bristol Myers Squibb** of cheating former **Celgene** shareholders by delaying federal approval for three drugs tied to contingent payments. - The appeals court issued a unanimous 3-0 decision finding that **UMB Bank** was entitled to represent Celgene shareholders as trustee despite an error in how it was appointed. - The litigation stems from Bristol Myers’ 2019 acquisition of Celgene for **$80.3 billion**, under which some Celgene shareholders held **contingent value rights (CVRs)** that would pay an extra **$9 per share** in cash if Bristol obtained timely U.S. regulatory approvals for three specified drugs. - The revived suit alleges Bristol delayed approvals, which the plaintiffs claim deprived Celgene shareholders of the CVR payments; the appeals court’s decision allows the case to proceed. - The article notes related reporting available to STAT+ subscribers, including a separate exclusive about a drug-testing lab suing the organization that develops drug standards, but full STAT+ content requires subscription. Details beyond the summarized points were not reported in the source.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/?utm_campaign=rss) [chronic disease](https://www.statnews.com/topic/chronic-disease/) [aging](https://www.statnews.com/topic/aging/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more ## Appeals court rules a judge erred in dismissing former Celgene shareholders’ suit against Bristol * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/14/lab-tests-lawsuit-bristol-multiple-myeloma-drug-approved/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Aug. 14, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, and hanging with a visiting short person. We also hope to have time for our weekly listening party, where the rotation will likely include [this](https://youtu.be/VbPz38Ijsfo?si=4AJaCmJhnnT7_VEr), [this](https://youtu.be/DfLp8-MYLAs?si=h8O2Abb82ZlP8sVg), [this](https://youtu.be/yRGYHvvTTTk?si=W5Ua8pFde5z-AEMk), [this](https://youtu.be/PKSSsbjztlY?si=QerO4wEwZ4udWkXG) and [this](https://youtu.be/GhSALyVvF7Y?si=W_nw599XW6fPneli). And what about you? As noted previously, this is a marvelous time to enjoy the great outdoors. City streets beckon. And beaches and woodsy trails are closer than you think. You could also curl up with a good book if the weather fails to cooperate, tidy around your castle, or get a head start on back-to-school shopping — the economy could always use a boost. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. … **The U.S. Food and Drug Administration approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission** , [STAT](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) explains. The drug, which will be sold under the brand name Zenbexus, is part of a Bristol research effort to develop a new and more potent class of blood cancer drugs called CELMoDs that work by redirecting a cell’s natural machinery to eliminate cancer-causing proteins. Advertisement **A U.S. appeals court ruled that a lower-court judge ‌erred in dismissing a $6.7 billion lawsuit accusing Bristol Myers Squibb of cheating former Celgene shareholders by delaying federal approval for three drugs** , [Reuters](https://www.reuters.com/legal/government/lawsuit-against-bristol-myers-over-delayed-cancer-drug-is-revived-2026-08-13/) writes. In a 3-0 decision, the appeals court decided UMB Bank was entitled to represent Celgene shareholders as a trustee despite ​an error in how it was appointed. The case arose from Bristol Myers’ purchase of Celgene for $80.3 billion in 2019. Celgene shareholders who ​held “contingent value rights” were entitled to an extra $9 per share in cash if Bristol Myers won timely ​U.S. regulatory approvals for three drugs. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-55908504-80x80.jpg) [Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths ](https://www.statnews.com/2026/08/11/stop-statins-age-75-lancet-study-suggests-safe-healthy-adults/) 2. ![](https://www.statnews.com/wp-content/uploads/2022/12/AdobeStock_251916311-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class](https://www.statnews.com/2026/08/14/fda-approves-bristol-multiple-myeloma-drug-zenbexus/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1880976507-80x80.jpeg) [MAHA and insurance companies both want to treat human bodies like cars](https://www.statnews.com/2026/08/14/health-insurance-companies-maha-surveillance/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2285913644-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Newsom promotes affordable insulin, but California’s generic label is off to a slow start](https://www.statnews.com/2026/08/13/newsom-california-generic-insulin-calrx-availability-slow-to-reach-patients/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_AIBillingSystem_F1_3000-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2025/08/VCFirms2025_LeftRailUnit-328x426.png) 2025 Edition: Ranking Biotech’s Top Venture Capital Firms ](https://reports.statnews.com/products/biotech-top-venture-capital-firms-2025) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2245399768-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [NIH plans to block international researchers on visas from accessing key funding avenue ](https://www.statnews.com/2026/08/07/nih-k99-pathways-independence-awards-scientists-on-visas-barred/) 2. ![](https://www.statnews.com/wp-content/uploads/2023/04/AdobeStock_521699065_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment](https://www.statnews.com/2026/08/10/itm-radiopharma-fda-rejection/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/STAT_AIBillingSystem_F1_3000-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care](https://www.statnews.com/2026/08/12/inside-commure-athelas-mad-dash-automate-health-care/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2269935478-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed](https://www.statnews.com/2026/08/10/china-biotech-new-scrutiny-investigator-initiated-trials/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/Schett-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies](https://www.statnews.com/2026/08/12/boulevard-bio-georg-schett-antibody-therapies/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Exclusive Exclusive August 14, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Drug-testing lab that has sparked controversy sues group that develops drug standards over criticism ](https://www.statnews.com/pharmalot/2026/08/14/controversial-lab-sues-usp-for-disparaging-its-testing-methods/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 13, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and more ](https://www.statnews.com/pharmalot/2026/08/13/california-insulin-sales-moderna-patent-battle/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 12, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more ](https://www.statnews.com/pharmalot/2026/08/12/lilly-black-market-lawsuits-trump-vaccine-plan-pushback/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugin
## Related Clinical Research

- [Link Between Daily Sugary Drink Consumption and Increased Stomach Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-1-daily-sugary-drink-consumption-linked-to-more-than-double-stomach-cancer-risk.md)
- [FDA approves Zenbexus (iberdomide) for multiple myeloma, first of a novel drug class](https://medichelpline.com/clinical-feed/stat-news-1-stat-fda-approves-bristol-multiple-myeloma-treatment-marking-debut-of-novel.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Trump administration announces nine additional drug pricing deals with manufacturers](https://medichelpline.com/clinical-feed/stat-news-1-trump-strikes-nine-more-deals-with-drugmakers-to-lower-prices.md)
- [Using a Genetic Inflammatory Index and Prakriti Stratification to Predict Inflammaging Risk](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-predicting-susceptibility-to-inflammaging-using-a-genetic-inflammatory-index.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.